The Central Social Insurance Medical Council, better known as Chuikyo, appears to see the need to set up new dosage…
HOME > REGULATORY
REGULATORY
- Average Price Gap for 2024 Revision Looks to Be Lower than 7.0%: Wholesalers
October 18, 2023
- AMED Group to Draft Master Protocols Guidelines by March-End, Frets Further Drug Lag/Loss
October 17, 2023
- MHLW Sets Up Hotline for Production Site Change for Supply-Crippled Drugs
October 17, 2023
- Health Minister Laments Drug Lag/Loss, Stresses Need for Govt-Driven Innovation Ecosystem
October 16, 2023
- MHLW Regulatory Panel OKs New Procedures for Post-Approval Manufacturing Changes
October 16, 2023
- Japan’s New Economic Package to Include Dementia Measures: PM
October 16, 2023
- Xarelto’s Label Expansion Up for Japan Panel Review on Oct. 27
October 16, 2023
- MHLW to Swiftly Deliberate Additional Purchase of COVID Jabs: Minister
October 16, 2023
- Label Revisions Ordered for G-CSF Agents, Yervoy and More
October 13, 2023
- MHLW Preparatory Council Boots Up for Japan-Version of CDC
October 13, 2023
- MHLW Panel Proposes Assessing Generic Makers’ Efforts toward Stable Supplies, Reflecting Results in Pricing
October 12, 2023
- Drug Innovation Measures Likely to Be Embraced in Govt Economic Package
October 12, 2023
- Vyvgart, Dysval Braced for Price Cuts after CEA, No Change for Ondexxya
October 12, 2023
- MHLW Pondering Every Possible Avenue to Supply Cough Drugs: Minister
October 11, 2023
- MHLW Set to Submit Bill to Lift Ban on Cannabis-Derived Drugs
October 11, 2023
- Japan Panel to Review Label Expansions for Opdivo, Adcetris, and More on Oct. 23
October 10, 2023
- Many Back Expansion in Range of CEA Price Tweaks for Pricey Drugs: Chuikyo
October 5, 2023
- Post-Launch Re-Pricing Likely the Focus of Chuikyo Leqembi Discussions
October 5, 2023
- WHO Recommends Takeda’s Dengue Vaccine in Children Ages 6-16
October 4, 2023
- MHLW Set to Wrap Up Drug Copay Debate by Year-End: Minister
October 4, 2023
ページ
Referrals can be an absolute game-changer in recruitment.When someone in your network recommends a candidate, they often have firsthand insight into the person’s skills, work ethic, values and ambitions. This insider knowledge results in higher quality candidates who are a…
Chugai Pharmaceutical’s Phesgo (pertuzumab + trastuzumab + vorhyaluronidase alfa) and Novartis’ Leqvio (inclisiran) will be newly added to the Japanese reimbursement list along with a batch of other medicines on November 22. Three drugs carry peak sales outlooks of over…
The main players in the FY2024 reimbursement policy reform are now all in place, with the roster rounded out by the appointment of former health minister Katsunobu Kato for the Liberal Democratic Party’s (LDP) prominent social security post at the…
A member of the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry on November 13…
A health ministry study group on pharmaceutical regulations on October 13 roughly agreed on a reform plan for Japanese regulatory…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…